^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Leiomyosarcoma
    Drug:unesbulin (BMIi-1) (BMI1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    PTC Therapeutics Press Release
    Title:

    PTC Therapeutics Announces Key Regulatory Designations for PTC596 to Advance Treatment of Two Rare Oncology Indications

    Published date:
    11/18/2020
    Excerpt:
    PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted PTC596 both Orphan Drug Designation and Fast Track designation for the potential treatment of leiomyosarcoma (LMS), a rare type of cancer that affects smooth muscle tissue.